Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Wariness Brewing within MHLW for Medical Fee to Incentivize Hospital Formularies
An all-important reimbursement policy panel on July 21 kicked off FY2022 reform discussions on a proposal to create a medical fee that would reward hospital formularies. The plan was dropped previously for the FY2020 reform in the face of doctors’…
To read the full story
Related Article
- Japan Unlikely to Introduce Medical Fee Incentives for Hospital Formularies in FY2022 Reform
December 20, 2021
- No Chuikyo Members Call for Formulary Incentives under Medical Fee Schedule
December 9, 2021
- 6.1% of Hospitals Have Established Formularies: Chuikyo Survey
March 25, 2021
- Japan Govt to Compile Formulary Guidelines by FY2022: Reform Timeline
December 21, 2020
- MHLW Collecting Evidence to Discuss Introduction of Medical Fee for Hospital Formularies in FY2022 Reimbursement Reform
November 18, 2020
- MHLW to Set Up Study Group to Investigate Formulary Initiatives at Hospitals: Pharmaceutical Management Director
September 25, 2020
- Chuikyo’s Draft Supplementary Opinions for 2020 Reimbursement Reform Calls for Medical Validity, Cost-Effective Analysis for Prescriptions
February 3, 2020
- Japan Forgoes Creation of Medical Fee to Reward Hospital Formularies in 2020 Reform
January 16, 2020
- Japan Likely to Take Pass on Rewarding Formulary Initiatives under Medical Fee Schedule
January 14, 2020
- Chuikyo Members Oppose Creation of Medical Fees for “Formularies” at Special Function Hospitals
December 16, 2019
REGULATORY
- Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
- CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
- MHLW Urges Stakeholders to Define Essential LLP Information
July 14, 2026
- Japan to Set Up Subgroup to Flesh Out Pharma Investment Roadmap: PM
July 13, 2026
- Immunization Act Revision Faces Uncertain Fate as Diet Clock Ticks Down
July 13, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…